Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Horizon Corporation Common Stock (FHN) vs Pfizer Inc (PFE) Price & Performance

First Horizon Corporation Common StockTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

First Horizon Corporation Common Stock vs Pfizer Inc — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Pfizer Inc trades at $29.33 (market cap $161.70B). The key difference: Pfizer Inc is far larger — about 15× First Horizon Corporation Common Stock's market cap, and Pfizer Inc pays the higher dividend (6.06%). Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Pfizer Inc for 158 Days on average.

FHNPFE
Market Cap
$10.79B$161.70B
Volume
8,579,46626,828,084
Sector
FinancialsHealth
52-Week High
$26.23$29.21
52-Week Low
$19.94$23.67
Typical Hold Time
0 Days158 Days
Enterprise Value
$14.10B$213.20B
Dividend Yield
2.99%6.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Horizon Corporation Common Stock

First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.

The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.

Pfizer Inc

Pfizer (PFE) trades at $28.40, up 0.42% with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights Pfizer's focus on AI drug discovery and a catalyst-rich pipeline in obesity and oncology for 2026, while analysts maintain a mixed consensus with 40% buy ratings.

Pfizer presents a balanced opportunity with stable cash flows and dividend payments, but faces headwinds from patent cliffs and declining net income margins. The stock trades near analyst consensus targets with moderate upside potential, though execution risks in pipeline development and competitive pressures warrant caution for growth-oriented investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FHN
100% Buy0% Sell
Avg holding period · 0 Days
PFE
88% Buy12% Sell
Avg holding period · 158 Days

Top news

Latest headlines on both assets

About First Horizon Corporation Common Stock

First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.

Read more on FHN →

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE →